​Furthermore, Axios reports the 2024 hopeful is now "best known for arguing that ESG and DEI run counter to fiduciary duty and can have undue influence on cultural change," pointing out that "ESG is an acronym standing for 'environmental, social and governance,'" while "DEI is an acronym standing for 'diversity, equity and inclusion.'"

No longer RSV's chief executive officer, Ramaswamy claims the company, formerly known as Roivant Foundation, was a "narrow scope with minimal resources," sans DEI initiatives at its start.

Axios notes RSV's website confirms it "partners with and sometimes invests in outside companies and groups to help create 'systemic improvements to health equity."

In defense of his current anti-ESG and DEI stance, Ramaswamy says, "Our business model was identifying abandoned drugs or areas that were languishing despite having tons of money poured into them, and we evaluated hundreds of these."

However, Axios also reports the company's current CEO "Lindsay Androski, wrote a September 2022 op-ed for the LA Times titled: 'Why the lack of diversity in drug industry leadership is hurting women and people of color.'"

Furthermore, RSV's website also says, "We hire motivated people with diverse backgrounds, identities, experiences and skillsets. We are committed to fostering an inclusive culture."